Glaucoma Eye Drops Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha agonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others (rho-kinase inhibitor, Cholinergic agonist), by Disease Indication (Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel (Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition (Preservative Free, BAK-Based and Non BAK-Based Preservatives), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), -

Published In : Jul 2023

Code : CMI3984

Pages :144

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Glaucoma Eye Drops Market: Key Developments

In November 2022, Alcon Management S. A.- an eye care company, completed the acquisition of Aerie Pharmaceuticals, Inc.- an ophthalmic pharmaceuticals company, to strengthen the company’s ophthalmic pharmaceutical business.

In July 2022, Novartis AG- a Switzerland-based multinational pharmaceutical corporation, announced that it has acquired Kedalion Therapeutics- developer of ophthalmic therapies, and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye to treat chronic diseases like glaucoma.

In June 2022, Amring Pharmaceuticals Inc. - a generic and brand pharmaceutical company, announced that it had received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%. The eye drops are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

In April 2022, A Japan-based post marketing observational study confirmed the safety and efficacy of omidenepag isopropyl ophthalmic solution 0.002% (OMDI), a topical drug used to treat elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension

Global Glaucoma Eye Drops Market: Key Trends

The increasing approvals by drug regulatory agencies across the globe with regard to glaucoma eye drops offer lucrative opportunities for the growth of the market over the forecast period. For instance, Visox Pharma- a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, announced that it had received notification from the U.S. Food and Drug Administration (FDA) that the agency had completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma.Visiox Pharma

In October 2022, Santen Pharmaceutical Co., Ltd. - a Japan-based pharmaceutical company, announced that the FDA approved OMLONTI, the company’s newest ophthalmic medication. This ophthalmic solution is composed of 0.002% omidenepag isopropyl. This drug will lower intraocular pressure (IOP) for patients with ocular hypertension or open-angle glaucoma.